Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it

On the subject in the title: Second pass at: Cagrilintide's dosing interval and the pharmacokinetics behind it Working notes rather than a conclusion.

A comparison question rather than a question about one compound.

Two things in the same family get discussed as though the evidence behind them were equivalent, and I do not think it is. One has a trial programme; the other has a mechanism and a following.

What is the fair way to describe the difference without being dismissive about the second?

This follows post #2 rather than contradicting it.

Research-use-only cagrilintide is not approved for human use and the published evidence base is a clinical-trial evidence base. Those two facts sit uncomfortably together and both are true.

I checked the source rather than the summary, and they differ.

The pharmacokinetics support weekly dosing comfortably. What the pharmacokinetics do not tell you is the tolerable escalation rate, and that is the practical constraint in every published protocol.

Cagrilintide molecular characteristics: it is a synthetic amylin analogue, substituted to prevent the amyloidogenicity of human amylin. The sequence is short and analytically straightforward to confirm by LC-MS.

It is the kind of thing that is obvious once and never again.

I read post #4 twice before replying, because I had assumed the opposite.

Cagrilintide is a long-acting amylin analogue, which puts it in a different mechanistic family from the incretin agonists it is usually discussed alongside. Amylin signalling contributes to satiety through a distinct pathway.

Where I would look next, rather than where I would stop.

Cagrilintide alone is discussed less than in combination because the published data is almost entirely from combination trials. The phase 2 combination data was consistent with more effect than either component alone, but phase 2 cannot establish whether that is synergy or simply additivity.